Cycling-Based Aerobic Exercise Intervention for Individuals With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Launched by MARGIE MCNEELY ·
Trial Information
Current as of September 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a specific type of exercise—stationary cycling—can help reduce symptoms of chemotherapy-induced peripheral neuropathy (CIPN), which is nerve damage some people experience after cancer treatment. The goal is to see if this exercise program is safe, doable, and helpful for improving nerve symptoms, fitness, and overall quality of life. This is a small, early-stage study that will help decide if a larger study should be done in the future.
The trial is looking to include about 30 adults with cancer, aged 65 to 74, who are experiencing symptoms of CIPN after chemotherapy. Participants will take part in supervised cycling sessions twice a week for 12 weeks, with each session lasting between 30 and 60 minutes. The exercise will gradually increase in intensity as participants improve. Throughout the study, researchers will check how well participants stick to the program, how satisfied they are, and if there are any safety concerns. This study has been approved by a health research board and is not yet recruiting.
Gender
ALL
Eligibility criteria
About Margie Mcneely
Margie McNeely is a dedicated clinical trial sponsor committed to advancing medical research through innovative and ethical study designs. With a focus on enhancing patient care and treatment outcomes, Margie brings extensive experience in trial management and regulatory compliance. Her collaborative approach fosters robust partnerships with healthcare professionals and research institutions, ensuring that clinical trials are conducted with the highest standards of integrity and scientific rigor. Passionate about improving healthcare solutions, Margie is dedicated to translating research findings into tangible benefits for patients and communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Margaret L McNeely, PhD
Principal Investigator
University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported